The ability to mount accelerated and efficient mucosal immune responses is critically important to prevent the establishment of many infections. Secretion of immunoglobulin A (IgA) is a key component in this first line of defense, but the underlying cellular mechanisms are still not completely understood. We have evaluated different routes of immunization and examined the requirements for IgA induction in the airway mucosa. We demonstrate that subcutaneous priming with a recombinant antigen in a T helper (Th)17-inducing adjuvant followed by airway boosting promotes high and sustained levels of IgA in the lungs. This response is associated with germinal center formation in the lung-draining lymph nodes. The lung IgA response is dependent on Th17 cells and absent if interleukin (IL)-17 is depleted or when priming with vaccines inducing only Th1 or Th2 responses. We used intravascular staining to demonstrate that IgA þ B cells and chemokine receptor 6 (CCR6) þ Th17 cells are recruited to the lung parenchyma after the airway booster immunization. Once recruited to the lung parenchyma, the Th17 cells transform into resident lymphocytes that persist in the lung tissue for at least 10 weeks. Here, they facilitate the accelerated recruitment of T and B cells resulting in an accelerated IgA recall response to a second airway booster immunization.
INTRODUCTION
Most pathogens use the external barriers of the airways, intestines, or genital tract as ports of entry, and the ability to mount an efficient mucosal immune response at these surfaces is critically important for protection against many pathogens. It is thus a high priority to understand the induction and maintenance of mucosal immune responses in order to generate efficient vaccines against mucosal pathogens.
It is known that mucosal and systemic immune systems are separated, and that lymphocyte priming in, e.g., the lungs will create strong tropism of those lymphocytes to the airways, whereas parenteral immunization induces systemic immunity. [1] [2] [3] Immunoglobulin A (IgA) is a critically important effector molecule at the mucosal surface. To date, little is known about the regulators of class switching to IgA, although transforming growth factor b, has been shown to have a direct role. [4] [5] [6] [7] It is also known that T helper (Th)17 cells are more abundantly present at the mucosal surface of the intestines, compared with other T-cell subsets, and intestinal interleukin (IL)-17 expression correlates with IgA secretion. 5 Th17 cells are furthermore suggested to be precursors for the follicular helper T (T FH ) cells that induce IgA class switch in Peyer's patches. 8 Less is known about the potential role of Th17 cells for IgA induction in the airways, though their involvment is suggested by their high prevalence in lung tissue during airway infections. 9, 10 It is known that intranasal administration of IL-17 upregulates epithelial polymeric immunoglobulin receptor (pIgR) expression and promotes influx of B cells and IgA into the lungs. 11 However, there is no evidence to suggest that Th17 cells have a direct role for IgA class switching and generation of IgA-producing plasma cells in the airways. Whether Th17 cells must be primed in the airways or distal mucosa-associated lymphoid tissues to acquire tropism to this tissue as observed after epicutaneous sensitazion 12 or if parenterally primed Th17 cells can be relocated and obtain tropism to the airways is an area of ongoing research.
In the present study, the aim was to examine the role of parenterally primed T cells for IgA induction in the airways. To induce high IgA titers, we present a vaccination protocol based on parenteral priming with the Th1/Th17-inducing adjuvant CAF01 13, 14 (Cationic Adjuvant Formulation no. 1), followed by an airway booster immuization. We find that the induction of IgA-producing B cells in the lungs correlates with rapid homing of systemically primed chemokine receptor 6 (CCR6)-expressing Th17 cells to the lung parenchyma and germinal center (GC) formation in the lung-draining lymph nodes (LNs). The Th17 cells are established as tissue resident cells that promote accelerated recall IgA responses. These findings challenge the current dogma that only local mucosal priming creates strong tropism of lymphocytes to the airways, which is of great relevance for the design of vaccines against airway pathogens and for the induction of local IgA at mucosal sites.
RESULTS

Increased IgA in the airways by parenteral priming and airway boosting
Our first aim was to establish an immunization protocol that provides a strong local IgA response in the airways. We therefore compared the ability of different prime-boost immunization strategies to induce lung IgA responses. Mice were immunized twice with CAF01 adjuvanted Group A streptococcal C5a peptidase (ScpA) by different combinations of subcutaneous (s.c.) and airway (intranasal, i.n.) administration routes. We then measured IgG1, IgG2a, IgA, and IgM antibodies in the lung homogenate supernatant and interferon (IFN)-g, IL-5, and IL-17 production by restimulated lung cells at days 1, 3, 7, 14, 21, 28, and 70, as well as IgA-producing plasma cells at day 14 after the booster immunization.
As depicted in Figures 1a,b ,e,f, the s.c./i.n. and s.c./s.c. immunizations resulted in high levels of IgG1 and IgG2a responses in lungs and serum. I.n./i.n. immunization for comparison gave IgG1 and IgG2a responses, 10-100-fold below the responses observed with the other strategies. The s.c./i.n. immunization resulted in a significantly elevated IgA titer already from day 7, which was maintained for at least 10 weeks in both lungs and serum (Figures 1c, g ). IgA was only transiently detected in the i.n./i.n. group after 2 weeks, after which the levels gradually returned to background levels 100-fold below the s.c./i.n. group. IgA was not detected in the lungs and serum after s.c/s.c. administration (Figures 1c, g ). IgA responses in bronchoalveolar lavage collected at day 14 correlated with those in lung homogenate supernatant (r 2 ¼ 0.9278; linear regression, n ¼ 18; data not shown). IgM was only detected in low amounts at day 7 (Figures 1d, h ). Utilizing area under the curve as a measure for antibody secretion over time showed that s.c./i.n. immunization gave markedly increased secretion of IgA compared with the other strategies (Supplementary Figure  S1A online). Correlating with these findings, s.c./i.n. immunization promoted high levels of T cells in the lungs, secreting high levels of cytokines (Figures 1i-k) . IFN-g and IL-5 levels were significantly elevated only at day 21 (Figures 1i, j respectively), whereas the IL-17 level was significantly elevated from day 3 and onwards ( Figure 1k) . I.n./i.n. immunization induced a slightly elevated (non-significant) IL-17 response compared with s.c./s.c. immunization at day 21 only.
The amount of ScpA-specific IgA antibody-secreting cells (ASCs) in perfused lungs increased significantly after s.c./i.n immunization to reach 76±21 IgA ASCs per million day 14 ( Figure 1l) . I.n./i.n. and s.c./s.c. immunization gave IgA ASC levels in the lungs comparable with background level in naïve mice (o20 IgA ASCs per million). As expected, no significant increase in IgA ASCs was observed in the spleen, for any of the groups (o20 IgA ASCs per million). The total amount of IgA ASCs in the lungs did not increase, suggesting no recruitment of non-related IgA ASCs (Supplementary Figure S1D) . We furthermore observed that the IgA induction was dependent on the adjuvant in the mucosal booster, because boosting with non-adjuvanted ScpA induced insignificant lung IgA responses (data not shown). In summary, only s.c./i.n. facilitated sustained IgA production over time and significantly enhanced local IgA ASC numbers. Elevated IgA responses thus correlated with elevated IL-17 responses in lungs as observed after s.c./i.n. immunization and to a lesser extent i.n./i.n. immunization.
To further study the influence of the priming vaccine on the induction of IgA in the lungs, we compared CAF01 priming with two different vaccine adjuvants known to promote markedly different T-cell profiles: aluminum hydroxide (Al(OH) 3 ; Th2-promoting) 15 and CpG Oligodeoxynucleotide (CpG; Th1-promoting).
16 CAF01 was used for the i.n. booster immunization in all groups. As illustrated in Figure 1m , priming with Al(OH) 3 and CpG resulted in a significantly lower IgA response in the lungs after boosting, compared with CAF01. To correlate this with the immune profile, we stimulated lung and spleen cells with the vaccine antigen and analyzed the secretion of IFN-g, IL-5, and IL-17 in culture supernatant (Figure 1n ). IFN-g release from splenocytes was promoted by both CpG and CAF01 (Figure 1n , top left), whereas only CAF01 priming mediated IFN-g induction in the lungs (Figure 1n , top right). IL-17 induction in the lungs and spleen was found only with CAF01 priming (Figure 1n , bottom). Al(OH) 3 gave very limited cytokine release, and only IL-5 reached a measureable level in the lungs (Figure 1n , middle right). Our data therefore suggest that the IgA promoted by the s.c./i.n. immunization by CAF01 is related to an IL-17 response induced by the priming immunization.
Parenteral prime and airway boost localize IgA þ B cells and Th17 cells in the lung parenchyma
We next studied in detail the B-and T-cell recruitment that takes place in s.c. primed animals during the airway boost (s.c./ i.n.) as compared with animals receiving a s.c. boost (s.c./s.c.), the latter inducing very similar IgG and IgG2a levels but no IgA. To first examine whether IgA þ B cells were localized in the lung parenchyma or in the lung vasculature, s.c./i.n. immunized mice were subjected to in vivo intravascular staining. This was conducted by injecting fluorescein isothiocyanate (FITC)-labeled anti-CD45 monoclonal antibody (mAb) intravenously (iv.CD45) 3 min before killing of the mice, thereby staining all intravascular, but not parenchymal, lymphocytes with Significantly increased levels of total CD4 þ T cells ( Figure 2d ) and Ag-specific cytokine producing (cyt þ ) CD44 þ CD4 þ T cells (Figure 2e ) in the lung parenchyma (iv.CD45 À ) were observed already at day 7. When comparing the subpopulation distributions in the lungs at days 0, 3, 7, and 14 in the s.c./i.n. group, it was evident that IL-17 þ CD44 þ CD4 þ T cells were recruited in an accelerated manner to the lung parenchyma compared with IFN-g þ CD44 þ CD4 þ T cells (Figure 2f ). These IL-17-and IFN-g-producing T cells were distinct populations (data not shown), as previously reported.
14 ScpA-specific IL-17-producing T cells preceded IFN-g-producing cells in the lung parenchyma already from day 3 and continued to outnumber IFN-g-producing cells at later time points (Figure 2f ), in agreement with the early IL-17 secretion from T cells isolated from the lung (Figure 1k ). The IL-17 þ population furthermore expressed higher levels of mucosal homing receptor CCR6 than both the IFN-g þ and cyt À CD44 þ CD4 þ T cells ( Figure 2g) .
We observed no ScpA-specific Th17 cells in the lung parenchyma and lung-draining LNs (tracheobronchial þ mediastinal, MLN þ TLN) after s.c. priming, very low but detectable levels in the inguinal LN (ILNs) draining the s.c. injection site (fourfold increase over non-immunized), and elevated IL-17 production by lymphocytes from peripheral blood (581 ± 307 vs. 36 ± 16 pg ml À l in non-immunized) (data not shown). Thus, the s.c./i.n. vaccine strategy led to increased localization of both IgA þ B cells and in particular Th17 cells in the lung parenchyma. As local secretion of IgA in the lungs of the s.c./i.n. immunized animals was closely associated with the early presence of IL-17-producing cells in the lungs after airway boost, we conducted a follow-up study where we compared the influx of IL-17-producing cells in the lung and lung-draining LNs (TLN þ MLN) in s.c./i.n., i.n./i.n., and s.c./s.c. immunized animals. On day 14 post booster immunization, significantly elevated levels of IL-17 þ CD44 þ CD4 þ T cells in lung parenchyma (iv.CD45 À ) were only observed after s.c./i.n. immunization although i.n./i.n. immunization also induced a slightly elevated (not statistically significant) response (Figure 2h) . A similar pattern was observed in the lung-draining LNs (TLN þ MLN; Figure  2i ), whereas significant responses in the ILNs draining the s.c. immunization site were observed only after s.c./s.c. immunization (Figure 2j ).
Depletion of CD4 cells or IL-17 ablates lung IgA responses
Having shown a positive correlation between recruitment of Th17 cells and lung IgA, we next investigated whether Th17 cells were required for IgA induction. After the s.c. priming immunization, systemic IL-17 was depleted by i.p. injection of 100 mg of anti-IL-17 mAb during booster immunization. As a positive control, CD4 þ T cells were depleted in a separate group. The experiment was terminated 10 days after boost, and homogenized perfused lungs were analyzed for humoral and cell-mediated immune responses. Intracellular cytokine staining (panel 2, Methods) of lung cells showed that IL-17 depletion reduced the proportion of activated CD44 þ CD4 þ T cells in the lungs from 4.99% in the isotype control group to 2.2% (Figure 3a left diagrams) . CD4 depletion led to a complete removal of CD4 cells in the lungs. Within the activated CD44 þ CD4 þ T cells, there was also a reduction in both IL-17 þ (from 1.21 to 0.32%) and IFNg þ T cells (from 0.8 to 0.01%; Figure 3a) . Both CD4 and IL-17 depletion led to a significant reduction in IgA titers in the lung ( Figure 3b top; B2 log reduction; Po0.001), whereas IgG was not significantly affected by the depletions (Figure 3b bottom) . These data demonstrated that IL-17 is essential for vaccine-induced IgA, but not IgG, responses in the airways.
T FH cells and GC formation is not observed in the lungs but in lung-draining LNs
Having confirmed that both B and T cells were recruited to the lung parenchyma during airway boost, we wanted to determine whether the B and T cells were localized in vaccine-induced tertiary lymphoid structures in the lung parenchyma or if GC formation was restricted to the draining LNs. We therefore investigated the induction of lymphoid GC B and T FH cells in lung tissue and TLN þ MLN.
Mice were immunized s.c./i.n., i.n./i.n., or s.c./s.c. and injected with anti-CD45 mAb before they were killed. TLN þ MLN, ILN, and lung cell suspensions were obtained on day 10 after booster immunization. Surface stainings were performed for detection of GC B cells Figures 4c, d) . Both s.c./i.n. and s.c./s.c. immunization protocols gave increased GC B cells in the ILN draining the site of the priming immunization, whereas GC B cells in the TLN þ MLN draining the lungs were found in high numbers after s.c./i.n. and i.n./i.n. immunization. None of the immunized animals showed evidence of GC B cells in the lung parenchyma (Figures 4a, b) . Similarly only the s.c./i.n. and i.n./i.n. groups promoted T FH cells in the lungdraining LNs. Only i.n./i.n. immunized mice had low but detectable T FH cell levels in the lung parenchyma (Figures 4c,  d) . In summary, these data suggest that airway boost (both after parenteral and mucosal prime) induces GC formation in the lung-draining LNs. ScpA, the cells were stained for CD4, CD44, CD69, CD62L, and IL-17 (panel 5, Methods). At this late time point, mice still had a significant population of CD4 þ CD44 þ IL-17 þ T cells (3.19%) in their parenchyma (Figure 5a ). More than half (66.4%) of the IL-17 þ CD44 þ CD4 þ T cells in the lung parenchyma were CD69 þ CD62L À tissue-resident memory T (T RM ) cells and the remaining were CD69-CD62L À effector memory T cells (Figure 5a ). This distribution was markedly different from IL17 þ T cells in the vasculature that contained only 17.2% CD69 þ CD62 À T RM cells but a substantial proportion of CD69-CD62L þ central memory T (T CM ) cells, not found in lung parenchyma (Figure 5a) .
To investigate whether the T RM cells had a role in a functional long-lived recall response, s.c./i.n., i.n./i.n. and s.c./s.c. immunized mice were given a second i.n. booster immunization 10 weeks after a completed immunization. A second boost resulted in 1-2 log higher IgA levels in the s.c./i.n. group compared with the i.n./i.n. and s.c/s.c. groups at all time points (Figure 5b) . Notably, the IgA levels in the mice from the s.c./i.n. group had significantly elevated ScpA-specific IgA at the time 0 of this experiment, i.e., at the time of the second booster immunization (Figure 5b) . Although i.n./i.n. immunization gave a substantial IgA response after the initial immunization (Figure 1c) , this protocol failed to induce IgA following late i.n. boost. For comparison, elevated IgA levels were detected in the s.c./s.c. group, but only 2 weeks after late i.n. boost (Figure 5b) . IL-17 induction was also highly accelerated and significantly higher in the s.c./i.n. group as compared with both s.c./s.c. and i.n./i.n. immunization (Figure 5c ). This suggests that IgA-secreting B cells and IL-17-producing T cells remain in the lung parenchyma after s.c./i.n. immunization.
Finally, we evaluated the relative role of tissue resident and newly recruited T and B cells from the LN in the accelerated recall response observed in the s.c./i.n. group. This was addressed by blocking cell exit from the LNs by treatment with fingolimod (FTY720) during a second i.n. booster immunization. Mice immunized s.c./i.n. were rested for 10 weeks. Thereafter, half of the animals received 70 mg fingolimod in 200 ml water orally per day from 2 days before and until 2 weeks after the i.n. boost. Before killing the mice, they received labeled anti-CD45 mAb iv and lungs were analyzed for IgA and Th17 cells. Both Th17 cells (Figure 5d ) and secreted IgA levels ( Figure 5e ) were significantly elevated by the i.n. boost, but fingolimod treatment almost completely abolished this booster effect. Only a minimal non-significant IgA increase was found in the fingolimod-treated animals. This suggests that the main role for tissue-resident Th17 cells in the lung parenchyma is to facilitate an accelerated recruitment of new B and T cells responsible for the rapidly emerging immunity in the lungs.
DISCUSSION
Little is known about the role of Th17 cells in the induction of IgA in the airways. Recent studies have demonstrated a Th17-mediated upregulation of pIgR expression by the epithelium accompanied by influx of B cells and transport of secretory IgA and IgM into the airways. 11, 18 However, the role of Th17 cells in In the present study, we introduce an optimized immunization protocol for induction of Th17 and IgA responses in the airways. We show for the first time that systemically induced Th17 cells are preferentially recruited to the lungs after airway exposure to the cognate Ag, and that this is accompanied by a local IgA response. We also show that depletion of IL-17 abrogates the recruitment of T cells to the lungs and significantly reduces the local IgA response as well as the Th1 response (IFN-g þ CD44 þ CD4 þ T cells). The latter observation has been reported previously by Khader et al. 21 showed that intestinal IgA was impaired in mice deficient in IL-17 or IL-21 signaling, but that only IL-21 is able to augment B-cell differentiation to IgA þ cells. In addition, Th17 cells may also increase expression of the pIgR in the airway epithelium, thus leading to increased secretory levels of IgA as reported by Jaffar et al. 11 Together with our data, these findings suggest that Th17 cells are important for both IgA isotype switch and local secretion of IgA not only in the gut, but also in the airway tissue.
It is well established that lymphocyte activation within a peripheral organ and/or its draining LNs will create tropism to that organ. However, our data suggest an ability of parenterally In a similar study, half of the mice that received the second boost (n ¼ 12) received FTY720 treatment by an oral stomach tube, from 1 day before until termination of the experiment day 7 after a second booster immunization. The mice were intravascular stained by iv injection of FITC-conjugated iv.CD45 and (d) Th17 cells and (e) IgA þ B cells in the parenchyma were analyzed by IC flow cytometry. Statistical analysis: one-way ANOVA using Tukey's post-test. *Po0.05. ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; IC, intra cellular; IL, interleukin; i.n., intranasal; MSD, Meso Scale Discovery; s.c., subcutaneous; ScpA, streptococcal C5a peptidase.
primed Th17 cells to home to mucosal tissues and establish themselves in these tissues as T RM cells. Thus, s.c./i.n. immunized mice mounted stronger Th17/IgA responses in the lungs than both s.c./s.c. and i.n./i.n. immunized animals.
Th17 cells are efficiently induced through mucosal infection or immunization 22, 23 and express tissue-selective homing receptors, such as CCR6. Indeed, we found that Th17 cells in the lungs expressed significantly higher levels of CCR6 than the Th1 cells, in support of previous observations, showing that CAF01-induced Th17 cells express higher levels of CCR6 than the Th1 subset. 14 The ability of Th17 cells to establish a strong memory response is controversial. Studies in mice have shown that mucosally imprinted Th17 cells are short-lived, 22 whereas studies in both primates and humans have detected Th17 memory cells after recovery from infection. 24, 25 Studies from our lab have previously shown that CAF01 induces a stable Th17 memory response by parenteral immunization in mice. 14 In line with this, we show here that Th17 cells and IgA þ B cells persist in lung parenchyma for at least 10 weeks after i.n. booster immunization, suggesting that Th17 cells can establish as T RM cells. Importantly, the presence of Th17 cells in the tissue facilitates accelerated recall responses with rapidly increasing IgA levels when the mice receive an i.n. booster immunization 10 weeks after s.c./i.n. immunization. Interestingly, this IgA recall response was not seen after late boost of i.n./i.n. immunization, although this protocol was associated with primary GC formation in the lung draining LNs and IgA production, suggesting that insufficient Th17 memory limits the ability to maintain a long-lived IgA recall response. Although most focus has been directed towards CD8 þ T RM cells, 26 recent data have demonstrated that CD4 þ T cells reside in the tissue as well. For instance, respiratory memory CD4 þ T cells in the lungs of mice and humans have phenotypes clearly distinct from those found in lymphoid tissue or in blood. 27 Moreover, influenza and M. tuberculosis lung infections induce CD4 þ T cells with selective tropism towards the lungs. 28, 29 All these studies show that the T RM cells express CD69, whereas the systemic T cells do not. In addition, CD69 expression is also associated with T RM cells in the skin, 30 genital tract, 31 and bone marrow. 32 Our data show that systemically primed Th17 cells establish CD62L-CD69 þ T RM cells in the lungs, whereas CD62L þ CD69 À T CM cells, classically found in lymphoid tissues, are absent (Figure 5a) . We did not observe any GC B cells and T FH cells in the lungs after s.c./i.n. immunization, indicating that tertiary lymphoid structures are not formed.
In summary, our data show that vaccine-specific Th17 cells induced by parenteral immunization are recruited to the lung parenchyma after airway boost where they facilitate the accumulation of IgA þ B cells and rapidly increasing local IgA levels. This is associated with T FH and GC formation in the regional LNs. The Th17 cells establish T RM cells that remain in the lung tissue, resulting in long-term increased levels of secreted IgA. This local memory results in highly accelerated Band T-cell recall responses in the lungs after another airway boost.
The role of Th17 cells in humans is not yet clear. However, there is increasing evidence supporting that Th17 cells have similar roles in humans and mice. 33, 34 Our data therefore suggest an immunization strategy for mucosal pathogens involving parenteral priming of a Th17 response followed by mucosal boosting. We demonstrate that this strategy results in the establishment of Th17 cells and high levels of local IgA in the airway. This strategy is particularly interesting, considering the need for safe vaccines with the ability to promote local immunity against infections of the lung, gut, and genital tract through a minimal number of mucosal immunizations. Recently published data from our laboratory have applied the CAF01 prime/intranasal boost strategy and demonstrated strong mucosal IgA responses to a chlamydia vaccine candidate in pigs. 35 This vaccine strategy is currently being prepared for human clinical trials. Antigens, adjuvant, and immunizations. The vaccine protein ScpA, described previously by Cleary et al. 36 (UniProt P15926), was recombinantly expressed in E. coli with an N-terminal His 6 -tag, affinity-purified, subjected to ion exchange chromatography, and analyzed by mass spectrometry and sodium dodecyl sulfate-polyacrylamide gel electrophoresis, as previously described.
37 CAF01 (DDA/TDB) 38 was used as the adjuvant at a dose of 250/50 mg. Mice were immunized by the subcutaneous route (s.c., volume 200 ml) at the base of the tail or intranasal (i.n., volume 2 Â 20 ml). Two immunizations were given with 2 weeks interval.
In vivo staining with anti-CD45.2. Anti-CD45.2-fluorescein isothiocyanate (clone 104; BD Biosciences, Albertslund, Denmark) was diluted to 10 mg ml À 1 in sterile phosphate-buffered saline (PBS); 250 ml of the solution was injected iv via the tail vein, 3 min before killing of the mice. FTY720 treatment. FTY720 (Sigma-Aldrich, Gillingham, UK) was diluted to 350 mg ml À 1 in sterile water for injection. Mice received 200 ml daily by stomach intubation from one day before until termination of the experiment.
Sample collection and cell preparation. Samples were collected from four to eight mice per group. Blood was obtained by submandibular bleeding. Lung cells were isolated by transferring lungs to gentleMACS C Tubes (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) containing 2 ml RPMI 1640, 5% fetal calf serum (FCS), and 0.8 mg ml À 1 Collagenase type IV (Sigma-Adrich, St. Louis, MO) and dissociated into 1-2 mm pieces using the gentleMACS Octo dissociator (Miltenyi Biotec GmbH), followed by 1 h incubation at 37 1C. The samples were returned to the gentleMACS and dissociated followed by centrifugation (700 Â g, 5 min). Supernatants were collected for antibody detection and the pellets were homogenized through cell-strainer (Falcon, Durham, NC) and washed twice in RPMI-1640 (Gibco Invitrogen, Hvidovre, Denmark). Cell cultures were performed in microtiter plates (Nunc, Roskilde, Denmark) containing 2 Â 10 5 cells per well (Meso Scale Discovery) or 1 Â 10 6 cells per well (fluorescence-activated cell sorting (FACS)/enzymelinked immunospot (ELISPOT)) in 100 ml RPMI-1640 (Gibco Invitrogen) supplemented with 5 Â 10 À 5 M 2-mercaptoethanol, 1 mM glutamine, 1% pyruvate, 1% penicillin-streptomycin, 1% HEPES, and 10% FCS (Gibco Invitrogen).
Antibody detection. Maxisorb Plates (Nunc) were coated with ScpA (0.5 mg ml À 1 ). Serum and lung samples were fivefold serially diluted 8-12 times from a 1:1 dilution on the plates. IgA was detected with horse radish peroxidase (HRP)-conjugated goat anti-mouse IgA mAb (Invitrogen, Hvidovre, Denmark) diluted 1:5,000. IgG1 was detected with HRP-conjugated goat anti-mouse IgG1 mAb (Southern Biotech, Birmingham, AL) diluted 1:20,000. IgG2a was detected with HRPconjugated rabbit anti-mouse IgG2a mAb (Invitrogen) diluted 1:5,000. IgM was detected with HRP-conjugated goat anti-mouse IgM mAb (Southern Biotech) diluted 1:5,000. Substrate was 3,3,5,5-tetramethylbenzidine-PLUS (Kem-En-TEC, Taastrup, Denmark). Reciprocal serum dilutions corresponding to the end point titer (cutoff Optical Density (OD) ¼ 0.1) were computed using GraphPad Prism v6.04 (GraphPad Software Inc., La Jolla, CA).
ELISPOT assay. IgA ELISPOT was performed according to the manufacturer's instructions (MABTECH AB, Nacka Strand, Sweden). Polyvinylidene fluoride plates (Millipore, Hellerup, Denmark) were pretreated with ethanol for 1 min and washed 5 Â with sterile water. The plates were then coated with 100 ml per well of ScpA solution (5 mg ml À 1 ) and incubated over night at 4 1C. The plates were washed 5 Â with PBS and blocked with 200 ml RPMI 1640 (Gibco Invitrogen) containing 10% FCS for 30 min at room temperature. After coating with 100 ml of cell sample (10 6 cells ml À 1 ) the plates were incubated for 24 h at 37 1C/5% CO 2 . The plates were washed in PBS five times and 100 ml anti-IgA-biotin (1 mg ml À 1 ) in PBS þ 0.5% FCS was added followed by 2 h incubation at room temperature. After 5 Â washing in PBS, 100 ml per well of Streptavidin-HRP (diluted 1:500 in PBS þ 0.5% FCS) was added followed by another 5 Â washing. Finally, 100 ml of 3,3,5,5-tetramethylbenzidine substrate (Kem-En-Tec) was added to each well and plates were developed until distinct spots emerged followed by washing in deionized water and drying for 24 h. Spots were counted using an automated ELISPOT Reader (AID, Strassberg, Germany).
MSD assays. In cytokine assays, cells were stimulated with 5 mg ml À 1 antigen and supernatants harvested after 72 h incubation at 37 1C/5% CO 2 . The levels of secreted cytokines were evaluated using Meso Scale Discovery assays. The Th1/Th2/Th17 cytokine 6-plex assay measuring IFN-g, TNF-a, IL-5, IL-10, IL-13, and IL-17 was performed using a MULTI-SPOT 96-well 7-Spot kit according to the manufacturer's instructions (Meso Scale Discovery, Gaithersburg, MD) and using a Sector Imager 2400 plate reader (Meso Scale Discovery).
Flow cytometric analysis. Cells were stimulated with 2 mg ml À 1 ScpA together with 1 mg ml À 1 anti-CD28 (37.51; BD Biosciences) and anti-CD49d (9C10; BD Biosciences) for 1 h and subsequently incubated for 5 h at 37 1C with 10 mg ml À 1 brefeldin A (SigmaAldrich) in addition. After overnight storage at 4 1C, cells were washed in FACS buffer (PBS containing 0.1% sodium azide and 1% FCS), and stained for 30 min at 4 1C (CXCR5: 60 min at room temperature) for surface markers with mAbs as indicated below. For intracellular staining, the cells were washed in FACS buffer, permeabilized using the Cytofix/Cytoperm kit (BD Biosciences), and stained for 30 min at 4 1C with mAbs as indicated below. Panel 1: anti-CD19-APC-eF780 (eBio1D3; eBioscience, San Diego, CA) anti-IgA-PE (mA-6E1; eBioscience). Panel 2: Surface; anti-CD4-APC-eF780 (RM4-5; eBioscience), anti-CD44-PE (IM7; BD Biosciences) and anti-CCR6-AF647 (140706; BD Biosciences), intracellular; anti-IFN-g-PE-Cy7 (XMG1.2; eBioscience, San Diego, CA) and anti-IL-17-PerCP-Cy5.5 (eBio17B7; eBioscience). Panel 3: anti-CD19-APC-eF780 (eBio1D3; eBioscience), anti-B220-PE-Cy7 (RA3-6B2; BD Biosciences), anti-IgD-PerCP-Cy5.5 (11-26c.2a; BD Biosciences), anti-CD95-APC (15A7; eBioscience) and anti-GL7-PE (GL7; BD Biosciences). Panel 4: Surface; anti-CD4-APC-eF780 (RM4-5; eBioscience), anti-CD44-APC (IM7; BD Biosciences), anti-CXCR5-PE (BD Biosciences) and anti-PD1-PE-Cy7 (RMP1-30; BioLegend, San Diego, CA), intracellular; anti-IL-17-PerCP-Cy5.5 (eBio17B7; eBioscience). Panel 5: Surface; anti-CD4-APC-eF780 (RM4-5; eBioscience), anti-CD44-APC (IM7; BD Biosciences), anti-CD62L-PE (MEL-14; BD Biosciences) and anti-CD69-PE-Cy7 (H1.2F3; BD Biosciences), intracellular; anti-IL-17-PerCP-Cy5.5 (eBio17B7; eBioscience). Cells were washed, resuspended in FACS buffer and analyzed using a FACSCanto flow cytometer (BD Biosciences). Responses were analyzed using FlowJo software v10.0.7. Doublets defined by FSC-A/FCS-H were removed from datasets before analysis.
Statistical analysis. Immune responses were compared by one-way analysis of variance followed by Tukey's multiple comparison test of the means or unpaired T tests. A value of Po0.05 was considered significant. Statistical analyses were performed in GraphPad Prism v6.04 (GraphPad Software Inc.).
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